Preferred Label : Tenofovir Disoproxil;
CAS number : F4YU4LON7I;
Origin ID : M000613540;
ATC code(s)
- Currated CISMeF NLP mapping
- Related record
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3262060/fr/reponses-rapides-dans-le-cadre-de-la-covid-19-prophylaxie-du-vih-par-tenofovir-disoproxil-/-emtricitabine-dans-le-cadre-de-l-urgence-sanitaire
2021
France
coronavirus infections
pneumonia, viral
guideline
Emtricitabine
emergencies
human immunodeficiency virus, nos
Tenofovir Disoproxil
Tenofovir
prophylactic treatment, nos
HIV
pandemics
COVID-19
---
https://www.has-sante.fr/jcms/p_3293341/fr/truvada-200-mg/245-mg-emtricitabine-/-tenofovir-disoproxil
2021
false
false
false
France
evaluation of the transparency committee
Tenofovir Disoproxil
fumarates
Truvada
reflex, babinski
cardiopulmonary resuscitation
Tenofovir
interdisciplinary medical team conference, nos
---
https://www.ema.europa.eu/en/medicines/human/EPAR/delstrigo
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Tenofovir Disoproxil
Tenofovir
lamivudine
DORAVIRINE
Tenofovir Disoproxil
DORAVIRINE
lamivudine
drug combinations
drug approval
europe
Tenofovir
lamivudine, tenofovir disoproxil and doravirine
adult
hiv infections
anti-hiv agents
anti-hiv agents
administration, oral
reverse transcriptase inhibitors
reverse transcriptase inhibitors
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
pyridones
triazoles
pyridones
triazoles
---
https://www.has-sante.fr/portail/jcms/c_2965623/fr/delstrigo
https://www.has-sante.fr/portail/jcms/c_2965623/fr/delstrigo-doravirine-lamivudine-tenofovir-disoproxil-association-d-antiretroviraux
2019
false
true
false
false
France
French
treatment outcome
Tenofovir Disoproxil
Tenofovir
lamivudine
DORAVIRINE
drug combinations
lamivudine, tenofovir disoproxil and doravirine
adult
hiv infections
anti-hiv agents
administration, oral
reverse transcriptase inhibitors
evaluation of the transparency committee
insurance, health, reimbursement
guidelines for drug use
HIV-1
doravirine
pyridones
triazoles
---
